Skip to content

SRTA SRTA Clinical — Goodwill

Other segment segments

Logistics
$15.54M

Similar metrics at other companies

Mesa Laboratories logo
MLABClinical Genomics — Goodwill
$17.12M+1.2%
Walker & Dunlop logo
WDCorporate — Goodwill
$0
Ashland logo
ASHLife Sciences — Goodwill
$462M-42.8%
National Healthcare logo
NHCInpatient Services — Goodwill
$5.92M0.0%
Sunbelt Rentals Holdings
 logo
SUNBSpecialty — Goodwill
$1.11B+6.6%
Tenet Healthcare logo
THCAmbulatory Care — Goodwill
$8.69B+7.4%

Other financials

Income statement

See full
Revenue$67.4M+87.4%
Gross profit$14.1M+100%
Operating income-$3.0M+47.7%
Net income$2.2M+162%
EPS (diluted)$0.03+175%

Balance sheet

See full
Cash & equivalents$59.0M+65.3%
Total debt$4.5M-50.7%
Total equity$285.7M+30.0%
Total assets$327.6M+30.8%

Cash flow

See full
Operating cash flow$3.9M+1,679%
CapEx$5.2M+98.1%
Free cash flow-$1.3M+54.8%

Valuation

See full
Market cap$463.78M+24.0%
Enterprise value$409.26M
P/E8.9×
P/S1.8×

Profitability

See full
Gross margin21.7%+1.3pp
Operating margin-7.8%-2.8pp
Net margin21%+13.6pp
FCF margin-22.4%+1,712pp

Returns & leverage

See full
Return on equity15.6%+10.0pp
Debt / equity0.0×
Current ratio5.9×-1.0×

Where this comes from

Reported directly by SRTA in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: SRTA’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about SRTA's clinical — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SRTA's clinical — goodwill?
SRTA (SRTA) reported clinical — goodwill of $73.05M in Q1 2026.
What does clinical — goodwill mean?
Represents the intangible asset value recorded when the clinical segment was acquired for a price exceeding the fair market value of its identifiable net assets. This balance reflects the premium paid for expected future economic benefits, such as brand reputation, customer relationships, or proprietary technology. Investors monitor this to assess potential impairment risks associated with past acquisitions within the clinical business unit.